Chester County News and Community Website
NEW HOPE, PA — In an ongoing endeavor to combat hypertension, Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has unveiled the latest results from a pressure-volume (PV) loop study of its …
Orchestra BioMed’s AVIM Therapy Demonstrates Promising Results in Controlling Hypertension Read More
PHILADELPHIA, PA — The tech firm Gaize is set to embark on an innovative clinical trial designed to study the effects of alcohol consumption on eye movements and pupil characteristics. …
Gaize Launches Groundbreaking Clinical Trial Studying Alcohol’s Impact on Eye Movements Read More NEW HOPE, PA — A new development in the management of hypertension could be a game-changer for patients with uncontrolled high blood pressure. Orchestra BioMed Holdings, Inc., a leading innovator …
Orchestra BioMed’s AVIM Therapy Shows Promising Long-Term Impact on Blood Pressure Read More
WAYNE, PA — Neuraptive Therapeutics, Inc. has unveiled compelling 24-week data from its ongoing NEUROFUSE study on NTX-001, bolstering the product’s status after the positive proof of concept results based …
Neuraptive Therapeutics Reports Encouraging 24-Week Data for NTX-001 in NEUROFUSE Study Read More
MALVERN, PA — Venatorx Pharmaceuticals, Melinta Therapeutics LLC, and the Menarini Group recently celebrated a significant medical breakthrough with the publication of the CERTAIN-1 Phase 3 clinical study results in …
Promising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIs Read More
HORSHAM, PA — Johnson & Johnson recently announced that the U.S. Food and Drug Administration (FDA) has granted approval for a reduced dosage frequency of its drug TECVAYLI® (teclistamab-cqyv) in …
FDA Greenlights Reduced Dosing Frequency for Johnson & Johnson’s TECVAYLI Read More
PLYMOUTH MEETING, PA — The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Harmony Biosciences Holdings, Inc.’s (Nasdaq: HRMY) pitolisant for the treatment of Prader-Willi syndrome …
Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a Pennsylvania-based clinical-stage drug platform company, has announced the completion of the last patient visit in the phase II/III study of its …
Annovis Bio Wraps Up Phase II/III Trial for Alzheimer’s Drug Buntanetap Read More
BALA CYNWYD, PA — The clinical-stage biotech firm Larimar Therapeutics has reported promising top-line data from its Phase 2 dose exploration study. The groundbreaking study tested the medication ‘nomlabofusp’ on …
Pioneering Leap for Friedreich’s Ataxia Treatment: Larimar Therapeutics Announces Encouraging Phase 2 Results for Nomlabofusp Read More
BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced initial positive results from a pilot study of its pain management drug candidate, Probudur™. The study was conducted under an …
Virpax Pharmaceuticals Reports Promising Results in Probudur Pilot Study Read More